| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total revenues | 238 | NaN | 0 | NaN |
| Cost of product sales | 14 | NaN | NaN | NaN |
| Research and development, net of tax credits | 3,251 | 3,940 | 3,669 | 4,978 |
| General and administrative | 4,824 | 3,263 | 3,759 | 5,167 |
| Commercial | 15,812 | 4,626 | 5,103 | 10,378 |
| Total operating expenses | 23,901 | NaN | NaN | NaN |
| Loss from operations | -23,663 | -11,829 | -12,531 | -20,523 |
| Interest income | 1,732 | 874 | 516 | 697 |
| Interest expense | 4,135 | 967 | 951 | 935 |
| Net loss and comprehensive loss | -26,066 | -11,922 | -12,966 | -20,761 |
| Basic EPS | -0.2 | -0.12 | -0.2 | -0.31 |
| Diluted EPS | -0.2 | -0.12 | -0.2 | -0.31 |
Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. (MIST)